Cg Oncology, Inc. (CGON) intrinsic value & 10-year financials
Cg Oncology, Inc. (CGON) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 345.0% a year to $4.0M, with an average return on invested capital of -18.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $59.85
- Market cap
- $4.6B
- Revenue (FY2025)
- $4.0M
- Revenue growth (4-yr CAGR)
- 345.0%
- ROIC (10-yr avg)
- -18.6%
- Free cash flow (FY2025)
- -$132.5M
CGON 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.0M | -$161.0M | -$2.08 | -$132.5M | -4722.1% | -31.7% |
| FY2024 | $1.1M | -$88.0M | -$1.41 | -$78.9M | -10067.3% | -66.4% |
| FY2023 | $204.0K | -$48.6M | -$1.12 | — | -27180.9% | 42.3% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CG Oncology, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CG Oncology, Inc. has historically struggled to out-earn its cost of capital, averaging just -18.6% ROIC.
CG Oncology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CG Oncology, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-69.09 per share.